Literature DB >> 29621127

Prognostic Factors of Uterine Serous Carcinoma-A Multicenter Study.

Xiaozhu Zhong1, Jianliu Wang1, Tengen Kaku2, Zhiqi Wang1, Xiaoping Li1, Lihui Wei1.   

Abstract

BACKGROUND: The prognostic factors of uterine serous carcinoma (USC) vary among studies, and there is no report of Chinese USC patients.
OBJECTIVE: The aim of this study was to investigate the clinicopathological characteristics and prognostic factors in Chinese patients with USC.
METHODS: Patients with USC from 13 authoritative university hospitals in China and treated between 2004 and 2014 were retrospectively reviewed. Three-year disease-free survival rate (DFSR), cumulative recurrence, and cumulative mortality were estimated by Kaplan-Meier analyses and log-rank tests. Multivariate Cox regression analysis was used to model the association of potential prognostic factors with clinical outcomes.
RESULTS: Data of a total of 241 patients were reviewed. The median follow-up was 26 months (range, 1-128 months). Median age was 60 years (range, 39-84 years), and 58.0% had stages I-II disease. The 3-year DFSR and cumulative recurrence were 46.8% and 27.7%. Advanced stage (III and IV) (P = 0.004), myometrial invasion (P = 0.001), adnexal involvement (P < 0.001), lymph node metastasis (P = 0.025), and positive peritoneal cytology (P = 0.007) were independently associated with 3-year DFSR. Advanced stage (P = 0.017), myometrial invasion (P = 0.008), adnexal involvement (odds ratio, 2.987; P = 0.001), lymph node metastasis (P = 0.031), and positive peritoneal cytology (P = 0.001) were independently associated with the cumulative recurrence. Myometrial invasion (P = 0.004) and positive peritoneal cytology (P = 0.025) were independently associated with 3-year cumulative mortality.
CONCLUSIONS: Peritoneal cytology and myometrial invasion could be independent prognostic factors for 3-year DFSR, cumulative recurrence, and cumulative mortality of patients with USC. Prospective studies are needed to confirm these results.

Entities:  

Mesh:

Year:  2018        PMID: 29621127     DOI: 10.1097/IGC.0000000000001272

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  4 in total

1.  Combined Adjuvant Chemotherapy and Radiation Therapy Improves Disease-Free Survival for Uterine Serous Cancer.

Authors:  Jessica D Arden; Kimberly Marvin; Hong Ye; Lena Juratli; Sirisha R Nandalur; Zaid Al-Wahab; Jayson Field; Jill Gadzinski; Joseph Anthony Rakowski; Barry Rosen; Maha Saada Jawad
Journal:  Adv Radiat Oncol       Date:  2020-10-24

2.  The Impact of Adjuvant Management Strategies on Outcomes in Women With Early Stage Uterine Serous Carcinoma.

Authors:  Andrew Cook; Remonda Khalil; Charlotte Burmeister; Irina Dimitrova; Mohamed A Elshaikh
Journal:  Cureus       Date:  2021-02-23

3.  Survival implication of lymphadenectomy in patients surgically treated for apparent early-stage uterine serous carcinoma.

Authors:  Jvan Casarin; Giorgio Bogani; Elisa Piovano; Francesca Falcone; Federico Ferrari; Franco Odicino; Andrea Puppo; Ferdinando Bonfiglio; Nicoletta Donadello; Ciro Pinelli; Antonio Simone Laganà; Antonino Ditto; Mario Malzoni; Stefano Greggi; Francesco Raspagliesi; Fabio Ghezzi
Journal:  J Gynecol Oncol       Date:  2020-09       Impact factor: 4.401

4.  Impact of positive cytology in uterine serous carcinoma: A reassessment.

Authors:  Logan Corey; Juliana Fucinari; Mohamed Elshaikh; Daniel Schultz; Rami Musallam; Feras Zaiem; Fayez Daaboul; Omar Fehmi; Greg Dyson; Julie Ruterbusch; Robert Morris; Michelle L Cote; Rouba Ali-Fehmi; Sudeshna Bandyopadhyay
Journal:  Gynecol Oncol Rep       Date:  2021-07-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.